PATENT CLAIM ANALYSIS

Application Number: 16015415
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "255060"]

Abstract:
In one embodiment, the invention provides a method of treating a subject who suffers from, or who is suspected of suffering from, a  Mycobacterium  infection, the method comprising administering to the subject a therapeutically effective amount of a urease inhibitor, optionally in combination with one or more anti-mycobacterial agents.

Claim (Index 54):
The method according to  claim 51 , wherein the one or more additional anti-mycobacterial agents are selected from the group consisting of isoniazid, ethionamide, aminosalicyclic acid/aminosalicylate sodium, capreomycin sulfate, clofazimine, cycloserine, ethambutol hydrochloride, kanamycin sulfate, rifabutin, rifampin, rifapentine, streptomycin sulfate, gatifloxacin,  15 N-ethionamide;  33 S-ethionamide,  34 S-ethionamide and  36 S-ethionamide; and  15 N-isoniazid and pharmaceutical salts and mixtures thereof.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 94.0
- Lexical Diversity: 1.48649
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15546680', '15792251', '16087161', '14426543', '15409911']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8197528485536203
- 35 USC 102 Novelty (BERT): 0.5147676978531919
- Combined Prediction Score: 0.7892543334835775
- Mean Citation Score: 299.08836
- Max Citation Score: 306.1570700000001
- Similarity Product: 219.5961735512204

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test